Table 2: Current experience with iVAC2L device.
Author, Year |
#N, pts |
Age (years) |
Device |
Access |
Indication |
Pre-IVAC |
Post-IVAC |
Complications* |
Vascular- site complications** |
Survival n/N |
||||
MAP (mmHg) |
PCWP (mmHg) |
CI (L/min/m2) |
MAP (mmHg) |
PCWP (mmHg) |
CI (L/min/m2) |
|||||||||
Tschope, 2020 [22] |
1 |
49 |
iVAC2L & VA ECMO |
Femoral Artery |
CS |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
No |
1/1 |
Tzikas, 2020 [43] |
1 |
46 |
iVAC2L |
Femoral Artery |
CS |
38 |
22 |
1.2 |
60 |
32 |
2.5 |
No |
No |
0/1 |
17 |
72 ± 9 |
iVAC2L |
Femoral Artery |
High-riskPCI |
81 ± 17 |
N/A |
N/A |
81 ± 17 |
N/A |
N/A |
1 |
1 |
17/17 |
|
Bastos, 2018 [45] |
1 |
70 |
iVAC2L |
Femoral Artery |
High-risk PCI |
N/A |
N/A |
1.27 (CO) |
N/A |
N/A |
1.29 (CO) |
No |
No |
1/1 |
Den Uil, 2017 [46] |
14 |
72 ± 8 |
iVAC2L |
Femoral Artery |
High-risk PCI |
66.5 ± 8.7 |
13.1 ± 6.4 |
2.2 ± 0.7 |
84.9 ± 9 |
11.2 ± 4.8 |
2.8 ± 0.8 |
2 |
No |
13/13 *** |
Arrigoni, 2011 [12] |
1 |
76 |
iVAC3L |
Pulmonary Artery Trunk to RV |
RV support in CS & IABP |
45 |
N/A |
2.88 (CO) |
75 |
ΝΑ |
3.3 (CO) |
1 |
No |
0/1 |
1 |
73 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
1/1 |
||||
Anastasiadis, 2011 [21] |
1 |
33 |
iVAC3L & VA ECMO |
Axillart Artery |
LV support due to ECMO use |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
No |
No |
1/1 |
Amico, 2008 [47] |
1 |
76 |
iVAC3L |
Aorta |
LV support during CABG |
74 |
N/A |
N/A |
83 |
N/A |
N/A |
No |
No |
1/1 |
Marianni, 2007 [48] |
14 |
69 ± 7 |
iVAC3L |
Aorta |
LV support during CABG |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
No |
No |
14/14 |
N: Number; pts: patients; N/A: not available; MAP: Mean Arterial Pressure; PCWP: Pulmonary Capillary Wedge Pressure; CI: Cardiac Index; CO: Cardiac Output; CS: Cardiogenic Shock; PCI: Percutaneous Coronary Intervention; LV: Left Ventricle; RV: Right Ventricle; CABG: Coronary Artrery Bypass Graft; VAECMO: Venous - Arterial Extracorporeal Membrane Oxygenation; IABP: Intra-Aortic Balloon Pump
*: any adverse event (acute kidney injury, stroke andtransient ischemic attack)
**: vascular bleeding, puncture site infection or swelling
***: one patient was excluded from post-procedural analyses